• Bookmark this Page
  • Print this Page

Myeloproliferative Disorders

Myeloproliferative Disorders, Symptoms and Causes

The Hematologic Malignancies program at the North Shore-LIJ Cancer Institute offers state-of -the-art diagnostic and therapeutic approaches for myeloproliferative disorders and other cancers of the blood and lymphatic systems. Our cancer experts are world renowned leaders in both the study and frontline treatment of hematologic cancers. They work closely with an interdisciplinary team of specialists to provide compassionate and individualized care using the latest protocols of chemotherapy, immunotherapy and targeted drug therapy.

Our Institute is one of the largest acute leukemia treatment centers in the nation. We have been designated a “Myelodysplastic Syndrome Center of Excellence” by the Myelodysplastic Syndrome Foundation. Our basic science research program for chronic lymphocytic leukemia led by Dr. Nicholas Chiorazzi and clinical therapeutic trials program under the leadership of Dr. Kanti Rai are models in their field and enjoy an international reputation for excellence.

Regional Leaders in Leukemia and Stem Cell Transplants

Our dedicated leukemia and stem cell transplant centers are among the largest in the New York area. Our Adult and Pediatric Bone Marrow and Stem Cell Transplant Programs are the only transplant programs in the Long Island, Queens, and Brooklyn area accredited by the prestigious Foundation for Accreditation in Cellular Therapy (FACT) for exceptional patient care and medical practices.

World Leaders in Chronic Lymphocytic Leukemia Treatment

Our Chronic Lymphocytic Leukemia Research and Treatment Program has become a world-renowned landmark for patients with chronic lymphocytic leukemia (CLL), one of the most common forms of leukemia in adults.

National Leaders in Leukemia Research

The Hematologic Malignancies Program is consistently listed among the top three medical centers for leukemia research in the United States. Our prominent researchers have led major trials through the Leukemia Group B (CALBG) and Community Clinical Oncology Program (CCOP), both supported by the National Cancer Institute (NCI). 

Myeloproliferative Disorders: An Overview

Myeloproliferative disorders are a group of diseases in which the bone marrow makes too many red blood cells, white blood cells or platelets.

There are six types of chronic myeloproliferative disorders. The specific type of myeloproliferative disorder is based on whether too many red blood cells, white blood cells or platelets are being made. Sometimes, the body will make too many of more than one type of blood cell, but usually one type of blood cell is affected more than the others are. Chronic myeloproliferative disorders include the following six types:

  • Chronic myelogenous leukemia
  • Polycythemia vera
  • Primary myelofibrosis (also called chronic idiopathic myelofibrosis)
  • Essential thrombocythemia
  • Chronic neutrophilic leukemia
  • Chronic eosinophilic leukemia

(Source: American Cancer Society)

Myeloproliferative Disorders Clinical Trials

The North Shore-LIJ Cancer Institute offers a full array of clinical trials. The result of this research not only impacts survival, but also enhances the quality of life. For more information about clinical trials for Myeloproliferative Disorders, visit Cancer Clinical Trials.

Make an appointment at the The embedded asset has been deleted:
Asset Type: eHA_Content_C
Asset Id: 1233806766368
PAGENAME: NSLIJ2/default_embed

The North Shore-LIJ Cancer Institute makes it easy for you to take the first steps in ensuring the best cancer care for yourself and your family. View the locations of our The embedded asset has been deleted:
Asset Type: eHA_Content_C
Asset Id: 1233816294922
PAGENAME: NSLIJ2/default_embed

Learn about the meeting times and locations for our The embedded asset has been deleted:
Asset Type: eHA_Content_C
Asset Id: 1233814156363
PAGENAME: NSLIJ2/default_embed
.

To learn more about the different types of cancer and treatment options, visit our The embedded asset has been deleted:
Asset Type: eHA_Content_C
Asset Id: 1233806766368
PAGENAME: NSLIJ2/default_embed
.